awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33958519-52BBA0C5-6D9F-4220-ADF4-C78ED8E4AF2B
Q33958519-52BBA0C5-6D9F-4220-ADF4-C78ED8E4AF2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33958519-52BBA0C5-6D9F-4220-ADF4-C78ED8E4AF2B
Emerging treatment options for patients with castration-resistant prostate cancer.
P2860
Q33958519-52BBA0C5-6D9F-4220-ADF4-C78ED8E4AF2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33958519-52BBA0C5-6D9F-4220-ADF4-C78ED8E4AF2B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9369e9a4e608439a2c987e1714af7fab50d616fd
P2860
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer